{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:27:34Z","timestamp":1783348054748,"version":"3.54.6"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100032301","name":"Samsung Bioepis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032301","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eculizumab, a humanized monoclonal antibody, inhibits activation of complement component C5. For patients with atypical hemolytic uremic syndrome, the introduction of eculizumab has markedly improved survival, restoring life expectancy close to that of the general population. The long-acting C5 complement inhibitor (CI) ravulizumab has since expanded treatment options, offering extended dosing intervals. In 2023, the first eculizumab biosimilars received market authorization. This study aims to evaluate the short-term economic impact of CIs from a German healthcare payer perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An economic model with weekly cycles and a time horizon of one year was developed to assess treatment costs for eculizumab originator, eculizumab biosimilars, and ravulizumab in adult patients with atypical hemolytic uremic syndrome, based on a standard adult body weight of 77.7\u00a0kg. The analysis included direct drug acquisition costs calculated on a milligram basis, obtained from publicly available German price databases and outpatient reimbursement regulations, as well as preparation costs for infusions. Treatment costs were analyzed up to 52 weeks to reflect short-term and annual treatment periods. All costs are presented in euros (2025), and no discounting was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Milligram-based prices were estimated at \u20ac12.92 for eculizumab biosimilar, \u20ac17.87 for eculizumab originator, and \u20ac13.63 for ravulizumab. After 13 weeks, cumulative costs were \u20ac124,941 (biosimilar), \u20ac172,466 (originator), and \u20ac127,062 (ravulizumab). After 52 weeks, costs reached \u20ac421,439, \u20ac581,836, and \u20ac352,463, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>At treatment initiation, the eculizumab biosimilar appears to be the most cost-efficient option among CIs in Germany, offering cost savings relative to both the originator and the long-acting agent. Sequential use of different CIs may therefore represent a cost-saving option.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-05118-2","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:08:18Z","timestamp":1783080498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complement inhibitor therapy in atypical hemolytic uremic syndrome (aHUS): evaluating the economic impact of introducing eculizumab biosimilars in Germany"],"prefix":"10.1186","volume":"27","author":[{"given":"Isabell","family":"Kaufhold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lewkowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danila","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Thomas","family":"Brinkkoetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"5118_CR1","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaim\u00e9 F, Dragon-Durey M-A, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol CJASN. 2013;8:554\u201362.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"5118_CR2","doi-asserted-by":"crossref","unstructured":"Orozco-Leal G, Vale L, Oluboyede Y, Brocklebank V, Bryant A, Chadwick T, et al. Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS. Nephrol Dial Transpl. 2025:gfaf166.","DOI":"10.1093\/ndt\/gfaf166"},{"key":"5118_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2215\/CJN.00620117","volume":"13","author":"V Brocklebank","year":"2018","unstructured":"Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol CJASN. 2018;13:300\u201317.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"5118_CR4","doi-asserted-by":"publisher","first-page":"1264310","DOI":"10.3389\/fmed.2023.1264310","volume":"10","author":"A \u00c1vila","year":"2023","unstructured":"\u00c1vila A, Cao M, Espinosa M, Manrique J, Morales E. Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults. Front Med. 2023;10:1264310.","journal-title":"Front Med"},{"key":"5118_CR5","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169\u201381.","journal-title":"N Engl J Med"},{"key":"5118_CR6","doi-asserted-by":"crossref","unstructured":"Vivarelli M, Barratt J, Beck LH, Fakhouri F, Gale DP, Jorge EG de, et al. The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2024;106:369\u201391.","DOI":"10.1016\/j.kint.2024.05.015"},{"key":"5118_CR7","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","volume":"124","author":"M Noris","year":"2014","unstructured":"Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014;124:1715\u201326.","journal-title":"Blood"},{"key":"5118_CR8","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89:701\u201311.","journal-title":"Kidney Int"},{"key":"5118_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/CLEP.S245642","volume":"12","author":"K Yan","year":"2020","unstructured":"Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clin Epidemiol. 2020;12:295\u2013305.","journal-title":"Clin Epidemiol"},{"key":"5118_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/ckj\/sfz066","volume":"13","author":"U Sch\u00f6nermarck","year":"2020","unstructured":"Sch\u00f6nermarck U, Ries W, Schr\u00f6ppel B, Pape L, Dunaj-Kazmierowska M, Burst V, et al. Relative incidence of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in clinically suspected cases of thrombotic microangiopathy. Clin Kidney J. 2020;13:208\u201316.","journal-title":"Clin Kidney J"},{"key":"5118_CR11","unstructured":"Statistisches Bundesamt. Bev\u00f6lkerung nach Nationalit\u00e4t und Geschlecht (Quartalszahlen). 2017."},{"key":"5118_CR12","unstructured":"Bundesministerium f\u00fcr Gesundheit. Gesetzliche Krankenversicherung. Mitglieder, mitversicherte Angeh\u00f6rige und Krankenstand Monatswerte Januar - Oktober 2025 (Ergebnisse der GKV-Statistik KM1) Stand: 31. Oktober 2025. 2025."},{"key":"5118_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ekir.2022.10.013","volume":"8","author":"RN Bouwmeester","year":"2023","unstructured":"Bouwmeester RN, Duineveld C, Wijnsma KL, Bemelman FJ, van der Heijden JW, van Wijk JAE, et al. Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study. Kidney Int Rep. 2023;8:91\u2013102.","journal-title":"Kidney Int Rep"},{"key":"5118_CR14","unstructured":"European Medicines Agency. Soliris: EPAR - Product information. 2025. Available at https:\/\/www.ema.europa.eu\/de\/documents\/product-information\/soliris-epar-product-information_de.pdf. Accessed at November 3, 2025."},{"key":"5118_CR15","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87:1061\u201373.","journal-title":"Kidney Int"},{"key":"5118_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, et al. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. Am J Kidney Dis Off J Natl Kidney Found. 2016;68:84\u201393.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"5118_CR17","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.ekir.2019.07.016","volume":"4","author":"E Rondeau","year":"2019","unstructured":"Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D. Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry. Kidney Int Rep. 2019;4:1568\u201376.","journal-title":"Kidney Int Rep"},{"key":"5118_CR18","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","volume":"97","author":"E Rondeau","year":"2020","unstructured":"Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, et al. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2020;97:1287\u201396.","journal-title":"Kidney Int"},{"key":"5118_CR19","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/13696998.2020.1831519","volume":"23","author":"Y Wang","year":"2020","unstructured":"Wang Y, Johnston K, Popoff E, Myren K-J, Cheung A, Faria C, et al. A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome. J Med Econ. 2020;23:1503\u201315.","journal-title":"J Med Econ"},{"key":"5118_CR20","unstructured":"European Medicines Agency. Ultomiris: EPAR - Product information. 2025. Accessed on November 3, 2025. Available at https:\/\/www.ema.europa.eu\/de\/documents\/product-information\/ultomiris-epar-product-information_de.pdf."},{"key":"5118_CR21","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s11560-019-0357-4","volume":"14","author":"CS Haas","year":"2019","unstructured":"Haas CS, Nitschke M, Menne J, Guthoff M, G\u00e4ckler A, Bruck H, et al. Charakterisierung von Patienten mit atypischem h\u00e4molytisch-ur\u00e4mischen Syndrom (aHUS) in Deutschland. Nephrol. 2019;14:496\u2013504.","journal-title":"Nephrol"},{"key":"5118_CR22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ndt\/gfx196","volume":"33","author":"KL Wijnsma","year":"2018","unstructured":"Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar NCAJ, Wetzels JFM. Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transpl. 2018;33:635\u201345.","journal-title":"Nephrol Dial Transpl"},{"key":"5118_CR23","doi-asserted-by":"publisher","first-page":"101392","DOI":"10.1016\/j.lanepe.2025.101392","volume":"56","author":"A Bryant","year":"2025","unstructured":"Bryant A, Lecouturier J, Orozco-Leal G, Brocklebank V, Carnell S, Chadwick T, et al. Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial. Lancet Reg Health - Eur. 2025;56:101392.","journal-title":"Lancet Reg Health - Eur"},{"key":"5118_CR24","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1182\/blood.2022017860","volume":"141","author":"F Fakhouri","year":"2023","unstructured":"Fakhouri F, Schwotzer N, Fr\u00e9meaux-Bacchi V. How I diagnose and treat atypical hemolytic uremic syndrome. Blood. 2023;141:984\u201395.","journal-title":"Blood"},{"key":"5118_CR25","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood.2020009280","volume":"137","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc A-L, Ville S, et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood. 2021;137:2438\u201349.","journal-title":"Blood"},{"key":"5118_CR26","unstructured":"European Medicines Agency. Epysqli - Eculizumab: European Public Assessment Report (EPAR) Public Assessment Report. EMA\/203468\/2023. 2023."},{"key":"5118_CR27","unstructured":"European Medicines Agency. Bekemv - Eculizumab: European Public Assessement Report (EPAR) Public Assessment Report. EMA\/114622\/2023. 2023."},{"key":"5118_CR28","unstructured":"Gemeinsamer Bundesausschuss. Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie: \u00a7 40b (neu) \u2013 Austausch von biotechnologisch hergestellten biologischen Fertigarzneimitteln durch Apotheken bei parenteralen Zubereitungen zur unmittelbaren \u00e4rztlichen Anwendung. 2024."},{"key":"5118_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14712598.2021.1849132","volume":"21","author":"S Simoens","year":"2021","unstructured":"Simoens S, Vulto AG. A health economic guide to market access of biosimilars. Expert Opin Biol Ther. 2021;21:9\u201317.","journal-title":"Expert Opin Biol Ther"},{"key":"5118_CR30","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.jval.2025.04.1903","volume":"28","author":"F Vuvu","year":"2025","unstructured":"Vuvu F, Porter J, Sacrest M, Arden M, Hirst A, Lashilola S. EE304 A Cost Minimization and Budget Impact Analysis of an Eculizumab Biosimilar, ABP 959, From the Spanish Healthcare Perspective. Value Health. 2025;28:S118.","journal-title":"Value Health"},{"key":"5118_CR31","unstructured":"Troein P, Newton M, Stoddart K, Travaglio M, Arias A. The impact of biosimilar competition in Europe. 2025."},{"key":"5118_CR32","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1681\/ASN.20203110S1576d","volume":"31","author":"E Rondeau","year":"2020","unstructured":"Rondeau E, Hatswell AJ, Cataland SR, Chen P, Freemantle N, Myren K-J, et al. Comparative Efficacy of Ravulizumab and Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome: An Indirect Comparison Using Clinical Trial Data: PO1851. J Am Soc Nephrol. 2020;31:576\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"5118_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.5414\/CN110516","volume":"97","author":"I Tomazos","year":"2022","unstructured":"Tomazos I, Hatswell AJ, Cataland S, Chen P, Freemantle N, Lommele \u00c5, et al. Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data. Clin Nephrol. 2022;97:261\u201372.","journal-title":"Clin Nephrol"},{"key":"5118_CR34","unstructured":"European Medicines Agency. Epysqli: EPAR - Product information. 2025. Available at https:\/\/www.ema.europa.eu\/de\/documents\/product-information\/epysqli-epar-product-information_de.pdf. Accessed on November 3, 2025."},{"key":"5118_CR35","unstructured":"Statistisches Bundesamt. K\u00f6rperma\u00dfe nach Altersgruppen und Geschlecht. 2025."},{"key":"5118_CR36","unstructured":"Das F\u00fcnfte Buch Sozialgesetzbuch \u2013 Gesetzliche Krankenversicherung \u2013 (Artikel 1 des Gesetzes vom 20. Dezember 1988, BGBl. I S. 2477, 2482), das zuletzt durch Artikel 1 des Gesetzes vom 25. Februar 2025 (BGBl. 2025 I Nr. 64) ge\u00e4ndert worden ist."},{"key":"5118_CR37","unstructured":"GKV-Spitzenverband. Vertrag \u00fcber die Preisbildung f\u00fcr Stoffe und Zubereitungen aus Stoffen, Anlage 3 Preisbildung f\u00fcr parenterale L\u00f6sungen, Stand 01. November 2025. 2025."},{"key":"5118_CR38","unstructured":"CompuGroup Medical AG. LAUER-TAXE\u00a9 Online 4.0. 2025. Available at https:\/\/lto.cgmlauer.cgm.com\/LTO40.160101\/taxe. Accessed November 1, 2025."},{"key":"5118_CR39","unstructured":"Umsatzsteuergesetz in der Fassung der Bekanntmachung vom 21. Februar 2005 (BGBl. I S. 386), das zuletzt durch Artikel 27 des Gesetzes vom 2. Dezember 2024 (BGBl. 2024 I Nr. 387) ge\u00e4ndert worden ist. 2025."},{"key":"5118_CR40","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s40620-021-01187-8","volume":"35","author":"M Cugno","year":"2022","unstructured":"Cugno M, Capone V, Griffini S, Grovetti E, Pintarelli G, Porcaro L, et al. Eculizumab treatment in atypical hemolytic uremic syndrome: correlation between functional complement tests and drug levels. J Nephrol. 2022;35:1205\u201311.","journal-title":"J Nephrol"},{"key":"5118_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/13696998.2022.2027706","volume":"25","author":"AR Levy","year":"2022","unstructured":"Levy AR, Chen P, Johnston K, Wang Y, Popoff E, Tomazos I. Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Med Econ. 2022;25:249\u201359.","journal-title":"J Med Econ"},{"key":"5118_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12959-016-0114-0","volume":"14","author":"Y-M Shen","year":"2016","unstructured":"Shen Y-M. Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome. Thromb J. 2016;14:19.","journal-title":"Thromb J"},{"key":"5118_CR43","unstructured":"Decision No 1295\/1999\/EC of the European Parliament and of the Council of. 29 April 1999 adopting a programme of Community action on rare diseases within the framework for action in the field of public health (1999 to 2003). OPOCE; 1999."},{"key":"5118_CR44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40259-025-00707-3","volume":"39","author":"JH Jang","year":"2025","unstructured":"Jang JH, Han B, Jung J, Russo P, Kulasekararaj AG. The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome. BioDrugs. 2025;39:281\u201395.","journal-title":"BioDrugs"},{"key":"5118_CR45","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. Available at https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed November 3, 2025."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05118-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05118-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05118-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:13:19Z","timestamp":1783347199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05118-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5118"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05118-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"I Kaufhold, D Lewkowicz, D Seidel and F Kron are employees of the VITIS Healthcare Group, which was sponsored by Samsung Bioepis in connection with the development of this manuscript. P Brinkkoetter received speaker honoraria and consultant fees from AstraZeneca, Alexion, Bayer, Boehringer-Ingelheim, Novartis, Roche, Sanofi-Genzyme, Travere, Vifor CSL and participated in advisory boards for Alexion, Samsung Bioepis, Sanofi-Genzyme, Novartis, TaregED Biopharmaceuticals, Travere, Takeda, Vifor CSL and Bayer. He declares research funding from the German Research Foundation BR-2955\/8 and Sanofi-Genzyme.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"402"}}